高龄心脑血管病患者口服阿司匹林的疗效与安全性研究  

Efficacy and satety of oral aspirin in advance-aged cerebro-cardiovascular disease patients

作　　者：赵海霞[1] 梁玉环[1] 

机构地区：[1]山东省泰山疗养院老年科,泰安271000

出　　处：《中华老年心脑血管病杂志》2014年第3期271-273,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的探讨高龄缺血性心脑血管病患者口服阿司匹林的疗效与安全性。方法回顾性分析在泰山疗养院长期住院的年龄≥80岁的缺血性心脑血管病患者235例,根据治疗分为阿司匹林组135例,非抗血小板组100例,比较2组心脑血管血栓性终点事件和出血事件的发生率。结果阿司匹林组联合终点事件29例,主要终点事件14例,血栓死亡7例,非抗血小板组分别39例、18例和11例,2组比较差异有统计学意义(P<0.01)。与非抗血小板组比较,阿司匹林组联合终点事件危险率降低81.4%,主要终点事件的相对危险下降73.1%,血栓事件死亡的危险下降111.5%(P<0.01)。阿司匹林组引起的严重出血事件3例,发生率2.2%,非抗血小板组无出血事件发生,2组出血事件比较,差异有统计学意义(P<0.05)。结论在密切监测情况下,年龄≥80岁的长期住院心脑血管病患者口服阿司匹林进行二级预防的疗效好,风险低,收益大于风险。Objective To study the efficiency and satety of oral aspirin in advance-aged ischemic cerebro-cardiovascular disease patients.Methods Two hundred and thirty-five ischemic cerebrocardiovascular disease patients with their age≥80 years were divided into aspirin treatment group （n=135） and non-antiplatelet treatment group （n=100）.Their cerebro-cardiovascular thrombotic end point events and bleeding events were retrospectively analyzed and compared.Results The risk of cerebro-cardiovascular thrombotic end point events and bleeding events was 81.4% lower,the relative risk of major end point events was 73.1% lower,and the risk of thrombotic events was 111.5% lower in aspirin treatment group than in non-antiplatelet treatment group （P〈 0.01）.Severe bleeding occurred in 3 patients （2.2%） of aspirin treatment group.No bleeding occurred in non-antiplatelet treatment group.Conclusion The efficiency and safety of oral aspirin are good for cerebro-cardiovascular disease patients with their age ≥80 years.

关 键 词：心血管疾病 脑血管障碍 阿司匹林 血小板聚集抑制剂 

分 类 号：R54[医药卫生—心血管疾病]